

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Haines, et al.
SERIAL NUMBER: 10/540,635 EXAMINER : Sean M. Basquill
FILING DATE: December 12, 2005 ART UNIT : 4161
FOR: ANTI-INFLAMMATORY FORMULATIONS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate; and
3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21534-002 CIP NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306
Attorney(s) for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: November 13, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Haines, et al.
SERIAL NUMBER: 10/540,635 EXAMINER : Sean M. Basquill
FILING DATE: December 12, 2005 ART UNIT : 4161
FOR: ANTI-INFLAMMATORY FORMULATIONS

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. Copies of the references (*) are not provided as they were previously cited or submitted to the USPTO in prior applications, Serial No. 10/621,802, filed July 16, 2003, and Serial No. 10/345,856, filed January 16, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Haines, et al.
U.S.S.N.: 10/540,635

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21534-002 CIP NATL.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306

Attorney(s) for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623


Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 13, 2008

4474181v.1

COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Haines, et al.
SERIAL NUMBER: 10/540,635 EXAMINER : Sean M. Basquill
FILING DATE: December 12, 2005 ART UNIT : 4161
FOR: ANTI-INFLAMMATORY FORMULATIONS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate; and
3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21534-002 CIP NATL. A duplicate copy of this transmittal letter is enclosed herewith.


Respectfully submitted,

LA Beattie

Ingrid A. Beattie, Reg. No. 42,306
Attorney(s) for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: November 13, 2008

Date of Deposit: November 13, 2008

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Haines, et al.
SERIAL NUMBER: 10/540,635 EXAMINER : Sean M. Basquill
FILING DATE: December 12, 2005 ART UNIT : 4161
FOR: ANTI-INFLAMMATORY FORMULATIONS

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. Copies of the references (*) are not provided as they were previously cited or submitted to the USPTO in prior applications, Serial No. 10/621,802, filed July 16, 2003, and Serial No. 10/345,856, filed January 16, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Haines, et al.
U.S.S.N.: 10/540,635

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21534-002 CIP NATL.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306

Attorney(s) for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 13, 2008

4474181v.1